These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 17586755)

  • 1. Treatment of arterial hypertension (AHT) associated with angiogenesis inhibitors.
    Dirix LY; Maes H; Sweldens C
    Ann Oncol; 2007 Jun; 18(6):1121-2. PubMed ID: 17586755
    [No Abstract]   [Full Text] [Related]  

  • 2. Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer.
    Ravaud A; Sire M
    Ann Oncol; 2009 May; 20(5):966-7; author reply 967. PubMed ID: 19403939
    [No Abstract]   [Full Text] [Related]  

  • 3. Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma.
    Frangié C; Lefaucheur C; Medioni J; Jacquot C; Hill GS; Nochy D
    Lancet Oncol; 2007 Feb; 8(2):177-8. PubMed ID: 17267332
    [No Abstract]   [Full Text] [Related]  

  • 4. From theoretical synergy to clinical supra-additive toxicity.
    Soria JC; Massard C; Izzedine H
    J Clin Oncol; 2009 Mar; 27(9):1359-61. PubMed ID: 19224836
    [No Abstract]   [Full Text] [Related]  

  • 5. [Renal cell carcinoma: the end of a tunnel?].
    Ravaud A; Dilhuydy MS
    Pathol Biol (Paris); 2006 May; 54(4):206-8. PubMed ID: 16530346
    [No Abstract]   [Full Text] [Related]  

  • 6. [Development of angiogenesis inhibitory combination therapies for treatment of renal cell carcinoma].
    Bartsch G; Eggert K; Soker S; Fiedler W; Laack E; Volkmer BG; Gschwend J; Bokemeyer C; Hautmann R; Schuch G
    Urologe A; 2007 Sep; 46(9):1289-90. PubMed ID: 17624513
    [No Abstract]   [Full Text] [Related]  

  • 7. Changes in central and peripheral blood pressure parameters during antiangiogenic treatment of metastatic renal cell carcinoma.
    Lipski D; Uruski P; Tomczak P; Adamiak J; Ramlau R; Tykarski A
    Pol Arch Intern Med; 2019 Dec; 129(12):942-944. PubMed ID: 31625532
    [No Abstract]   [Full Text] [Related]  

  • 8. Interview with professor Per-Anders Abrahamson: angiogenesis and renal cell carcinoma.
    Abrahamson PA
    Eur Urol; 2006 Sep; 50(3):609-11. PubMed ID: 16824676
    [No Abstract]   [Full Text] [Related]  

  • 9. [Not Available].
    Mery B; Thiery-Vuillemin A; Massard C; Albiges L; Magné N
    Bull Cancer; 2018 Dec; 105 Suppl 3():S219-S220. PubMed ID: 30595149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-2 continuous infusion and angiogenesis surrogate markers in metastatic renal cell carcinoma.
    Simonelli C; Talamini R; Bearz A; Berretta M; Spazzapan S; Monini P; Sgadari C; Sartor I; Ensoli B; Tirelli U
    Ann Oncol; 2006 Aug; 17(8):1335-6. PubMed ID: 16569648
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-term response to pazopanib in an elderly man with mRCC. A case report.
    D'Aniello C; Cavaliere C; Pisconti S; Facchini G
    Tumori; 2014; 100(6):e305-8. PubMed ID: 25688517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Revision of therapeutic index for targeted treatment in kidney cancer: What if toxicity could predict efficacy?].
    Grellety T; Brugères-Chakiba C; Chaminade A; Roubaud G; Ravaud A; Gross-Goupil M
    Bull Cancer; 2014 Jun; 101(6):608-18. PubMed ID: 24977449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do the results of the new trials change the standard treatment of metastatic renal cell cancer?
    Mulder SF; van Spronsen DJ; De Mulder PH
    Onkologie; 2007 May; 30(5):260-4. PubMed ID: 17460422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impaired endothelium-dependent vasodilation does not initiate the development of sunitinib-associated hypertension.
    Thijs AM; van Herpen CM; Verweij V; Pertijs J; van den Broek PH; van der Graaf WT; Rongen GA
    J Hypertens; 2015 Oct; 33(10):2075-82. PubMed ID: 26203967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of anti-angiogenic treatments on metastatic renal cell carcinoma.
    Ainsworth NL; Lee JS; Eisen T
    Expert Rev Anticancer Ther; 2009 Dec; 9(12):1793-805. PubMed ID: 19954291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Angiogenesis and renal cell carcinoma].
    Billemont B; Méric JB; Izzedine H; Taillade L; Sultan-Amar V; Rixe O
    Bull Cancer; 2007 Jul; 94 Spec No():S232-40. PubMed ID: 17846009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hypertension and palmar plantar erythroderma. Management of adverse events of angiogenetic inhibitors in the treatment of renal cell carcinoma].
    Rolfes N; Lümmen G
    Urologe A; 2011 Nov; 50(11):1387-91. PubMed ID: 21800197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case records of the Massachusetts General Hospital. Case 17-2008. A 63-year-old man with metastatic renal-cell carcinoma.
    Michaelson MD; Iliopoulos O; McDermott DF; McGovern FJ; Harisinghani MG; Oliva E
    N Engl J Med; 2008 May; 358(22):2389-96. PubMed ID: 18509125
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of antiangiogenic therapy.
    von Falck C; Wacker F; Rosenthal H
    J Vasc Interv Radiol; 2012 Nov; 23(11):1503. PubMed ID: 23101922
    [No Abstract]   [Full Text] [Related]  

  • 20. Antitumor and antiangiogenic activity of cediranib in a preclinical model of renal cell carcinoma.
    Medinger M; Esser N; Zirrgiebel U; Ryan A; Jürgensmeier JM; Drevs J
    Anticancer Res; 2009 Dec; 29(12):5065-76. PubMed ID: 20044618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.